Patents by Inventor Brian Czerniecki

Brian Czerniecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ESR1 DERIVED PEPTIDES AND USES THEREOF FOR NEOANTIGEN THERAPY
    Publication number: 20240091359
    Abstract: Disclosed are compositions neoantigens and T cell receptors (TCRs) specific for one or more neoantigens as well as methods of their use for treating cancer.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 21, 2024
    Inventors: Brian Czerniecki, Loretta Loftus, Gabriella K. Albert
  • COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY
    Publication number: 20240050544
    Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
    Type: Application
    Filed: April 27, 2023
    Publication date: February 15, 2024
    Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
  • COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC
    Publication number: 20240009232
    Abstract: Disclosed are anti-cancer therapies comprising i) at least one dendritic cell pulsed with an oncodriver and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor and methods of the use of said therapies to treat cancer.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 11, 2024
    Inventors: Krithika N. KODUMUDI, Brian CZERNIECKI
  • COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE, A PROBIOTIC, AND SEMAPHORIN
    Publication number: 20230390345
    Abstract: Disclosed are anti-cancer therapies comprising i) at least one dendritic cell pulsed with an oncodriver and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor and methods of the use of said therapies to treat cancer.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 7, 2023
    Inventors: Krithika N. KODUMUDI, Brian CZERNIECKI
  • Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
    Patent number: 11660330
    Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 30, 2023
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., VACCINEX, INC.
    Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
  • COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY
    Publication number: 20200397881
    Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 24, 2020
    Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans